Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Eagle Pharmaceuticals (EGRX) Tops Q3 EPS by 12c
November 9, 2016 6:51 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.77, $0.12 better than the analyst estimate of $0.65. Revenue for the quarter came in at $37.8 million versus the consensus estimate of $41.04 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More